Back to news

Vaxcyte slips as investors digest recent financing after Phase 3 vaccine data

Investivoq PriceTracker

Vaxcyte (PCVX) is down 3.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued digestion of Vaxcyte’s large early-October financing, which came just after a major clinical update. There does not appear to be a fresh company-specific negative announcement today, so the pullback looks more like financing-related pressure and profit-taking after a sharp rally earlier this month. This could be because investors are reassessing dilution and convertible note overhang while waiting for the next VAX-31 milestones.

Details:

  • Earlier in October, Vaxcyte reported positive topline results from the Phase 3 OPUS-1 trial for VAX-31, a key adult pneumococcal vaccine candidate.
  • On the same date, the company announced concurrent public offerings of common stock, pre-funded warrants and convertible senior notes to raise capital for development, manufacturing scale-up and launch preparation.
  • Vaxcyte later priced and then closed those offerings, with the combined transaction totaling about $1.15 billion, increasing the market’s focus on dilution and future conversion risk.
  • Today’s move happened without an obvious new corporate catalyst, which suggests the stock may be trading on positioning, recent issuance effects and near-term biotech volatility.

    • Sources:

    Vaxcyte, SEC, Nasdaq

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $PCVX Insider Trading Activity

    PCVX Insider Trades

    $PCVX insiders have traded $PCVX stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.

    Here’s a breakdown of recent trading of $PCVX stock by insiders over the last 6 months:

    • GRANT PICKERING (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 19 sales selling 66,896 shares for an estimated $3,634,849.
    • JIM WASSIL (EVP, Chief Scientific Ofc, COO) has made 0 purchases and 15 sales selling 33,192 shares for an estimated $2,424,751.
    • ELVIA COWAN (SVP, Finance & CAO) sold 19,000 shares for an estimated $1,648,060
    • ANDREW GUGGENHIME (PRESIDENT AND CFO) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $1,641,716.
    • HARPREET S. DHALIWAL (Chief Technical Ops Officer) sold 17,000 shares for an estimated $935,068

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive PCVX Data Alerts
    Get market-moving data, filings, and signals for PCVX in real time.
    Sign Up

    $PCVX Hedge Fund Activity

    We have seen 181 institutional investors add shares of $PCVX stock to their portfolio, and 139 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 5,524,774 shares (+82.7%) to their portfolio in Q2 2026, for an estimated $321,155,112
    • FMR LLC added 4,360,046 shares (+26.4%) to their portfolio in Q2 2026, for an estimated $253,449,473
    • PARADIGM BIOCAPITAL ADVISORS LP removed 2,665,168 shares (-55.6%) from their portfolio in Q2 2026, for an estimated $154,926,215
    • PRICE T ROWE ASSOCIATES INC /MD/ added 2,012,570 shares (+206.1%) to their portfolio in Q2 2026, for an estimated $116,990,694
    • D. E. SHAW & CO., INC. removed 1,729,181 shares (-47.6%) from their portfolio in Q2 2026, for an estimated $100,517,291
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,464,812 shares (+inf%) to their portfolio in Q2 2026, for an estimated $85,149,521
    • WELLINGTON MANAGEMENT GROUP LLP added 1,386,968 shares (+24.7%) to their portfolio in Q2 2026, for an estimated $80,624,449

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $PCVX Congressional Stock Trading

    Members of Congress have traded $PCVX stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

    Here’s a breakdown of recent trading of $PCVX stock by members of Congress over the last 6 months:

    • REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 3 purchases worth up to $45,000 on 07/16, 05/13, 05/12 and 0 sales.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.